CELSET Launches SOLTOX Botulinum Toxin Brand for International Markets

South Korean biotechnology company CELSET INC. has launched SOLTOX, a type A botulinum toxin brand designed for the international medical aesthetics sector. The product introduction aims to expand the company's global footprint while emphasizing technical specifications and controlled manufacturing processes.

Product Specifications and Formulations

SOLTOX is presented in 100-unit and 200-unit formulations, defined by three core technical characteristics:

• 900 kDa Toxin Complex: Identifies the molecular size of the protein complex, including associated proteins, without establishing any claims of superior clinical duration or efficacy.
• Lyophilized Dosage Form: Supplied as a freeze-dried powder requiring reconstitution prior to administration by qualified medical professionals.
• Advanced Purification Process: Focuses on separating the desired substance from undesired materials under controlled production and quality control conditions.

Regulatory Compliance and Market Presence

CELSET emphasizes that the formulation and purification metrics serve as a technical baseline rather than a guarantee of differentiated clinical results. The brand positions itself around transparent product identity and scientific communication tailored for medical professionals.

Availability and usage remain strictly subject to local regulatory frameworks and product labeling requirements in each target country. Stakeholders seeking further details can review official corporate announcements or consult the company's primary communication channels.